Table 1. Baseline characteristics and major outcomes of the included studies.

Authors	Trial	Year	SGLT2i	n	SGLT2i group	Placebo group	Age, yrs	Males, %	Diabetes mellitus, %	All-cause mortality events			Heart failure hospitalizations events			Cardiovascular deaths events
										SGLT2i group	Placebo group		SGLT2i group	Placebo group		SGLT2i group	Placebo group
SGLT2i: sodium-glucose co-transporter-2 inhibitors.
Rådholm K, et al.[16]	CANVAS	2018	Canagliflozin	1,461	803	658	63.8	56	100	84	92		41	67		70	75
Fitchett D, et al.[17]	EMPAREG	2016	Empagliflozin	706	462	244	64.5	70	100	56	35		48	30		38	27
Packer M, et al.[11]	EMPEROR reduced	2020	Empagliflozin	3,730	1,863	1,867	66.9	76	49.8	249	266		246	342		187	202
McMurray JJV, et al.[8]	DAPA-HF	2019	Dapagliflozin	4,744	2,373	2,371	66.4	77	41.8	276	329		231	318		227	273
Cosentino F, et al.[18]	VERTIS CV	2020	Ertugliflozin	1,958	1,286	672	64.4	68	100	150	81		69	55		116	64
Bhatt DL, et al.[19]	SOLOIST WHF	2021	Sotagliflozzin	1,222	608	614	69.5	66	100	65	76		194	297		51	58
Kato ET, et al.[20]	DECLARE TIMI-58	2019	Dapagliflozin	1,987	980	1,007	64.0	71	100	122	149		92	130		79	85
Nassif ME, et al.[21]	DEFINE-HF	2019	Dapagliflozin	263	131	132	61.3	73	63.1	1	1		10	8		1	1
Sarraju A, et al.[22]	CREDENCE	2021	Canagliflozin	652	329	323	65.2	61	100	45	44		34	36		−	−